Enter your login e-mail to the account
Search
- B‑ lymphocyte‑ targeted MS therapy: from theory to a decade of ocrelizumab in practice
MUDr. Dominika Šťastná, Ph.D., MUDr. Jana Seňavová, prof. MUDr. Dana Horáková, Ph.D.
(2/2024, Review articles ) - Early highefficacy mulitple sclerosis treatment: therapeutic success despite safety barriers
MUDr. Dominika Šťastná, Ph.D., prof. MUDr. Manuela Vaněčková, Ph.D., doc. MUDr. Dana Horáková, Ph.D.
(6/2023, Case reports ) - High efficacy treatment since the first attack – an important step in the treatment of multiple sclerosis?
MUDr. Dominika Šťastná, MUDr. Ingrid Menkyová, doc. MUDr. Dana Horáková, Ph.D.
(1/2023, Review articles ) - Ocrelizumab since the first multiple sclerosis attack – a milestone in reimbursement criteria
MUDr. Dominika Šťastná, MUDr. Ingrid Menkyová, doc. MUDr. Dana Horáková, Ph.D.
(4/2022, Review articles ) - MS and NMOSD during the pandemic COVID-19 – what have we already learnt?
MUDr. Dominika Šťastná, MUDr. Ingrid Menkyová, doc. MUDr. Dana Horáková, Ph.D.
(4/2021, Review articles ) - The influence on long-term progression of multiple sclerosis – brighter days ahead?
MUDr. Dominika Šťastná, doc. MUDr. Dana Horáková, Ph.D.
(1/2021, Review articles )